WHO approves Bavarian Nordic’s mpox vaccine for adolescents
The World Health Organization said on Monday, October 14 that it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the disease that has triggered global concern.
The WHO said in a statement that it gave the Jynneos vaccine prequalification for adolescents on October 8.
Children, adolescents and those with weakened immune systems have been particularly vulnerable to mpox, a viral infection that typically causes flu-like symptoms and skin lesions filled with pus.
WHO's latest decision comes after the EU approved the drug for the vaccine for adolescents in September.
Published - October 14, 2024 04:33 pm IST
Ads
Recent Health News
Trending News
)
Recent News
)
)
)
)
)
